Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma MAGNETISMM-4
Verified

What's the purpose of this trial?

The goal of this clinical trial is to evaluate the best dose, safety and effectiveness of elranatamab when combined with different anti-cancer therapies in participants with multiple myeloma.

This trial is currently open and accepting patients.


What will happen during the trial?

This clinical trial is being conducted in several different sub-studies. This trial is open-label, which means that participants and the study team will know which part participants are enrolled in, and which drugs / doses they will be receiving. Two sub-studies are currently open and enrolling participants.

After the end of the study, researchers may ask you to have monthly follow up visits, or telephone calls with the study team every few months.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable multiple myeloma as determined by the trial protocol.
  • have multiple myeloma that is refractory to at least one immunomodulatory drug, one proteasome inhibitor, and one anti-CD-38 antibody.
  • do not have primary refractory multiple myeloma.
  • have received at least three prior lines of therapy for multiple myeloma.
  • have not previously received either an anti-BCMA bispecific antibody or any kind of therapy targeting BCMA depending on the sub-study currently open (BCMA is the target of the combination of drugs tested against multiple myeloma).
  • have adequate heart, liver, kidney and bone marrow function as described in the trial criteria.

Additional Trial Information

Phase 1/2

Enrollment: 370 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Arizona

Banner MD Anderson Cancer Center at Banner Gateway Medical Center

Gilbert, AZ

Not Yet Accepting

University of Arizona Cancer Center - North Campus

Tucson, AZ

Not Yet Accepting

California

Beverly Hills Cancer Center

Beverly Hills, CA

Open and Accepting

Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Los Angeles, CA

Not Yet Accepting

Florida

Sylvester Comprehensive Cancer Center University of Miami Health System

Miami, FL

Open and Accepting

Illinois

University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Open and Accepting

Iowa

Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Not Yet Accepting

Kansas

University of Kansas Cancer Center

Kansas City, KS

Not Yet Accepting

Massachusetts

Massachusetts General Hospital

Boston, MA

Not Yet Accepting

Washington

Seattle Cancer Care Alliance SCCA

Seattle, WA

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors